Stable Sulforaphane Targets Early Stages of Osteoclast Formation to Engender Lasting Functional Blockade of Osteoclastogenesis

Abstract

Sulforaphane, the native but unstable form of SFX-01, is an antioxidant that activates NRF2 and inhibits NF-KB pathways to achieve its actions. Resolving the mechanism(s) by which SFX-01 serves to control the various osteoclastogenic stages may expose pathways that could be explored for therapeutic use. Here we seek to identify the stage of osteoclastogenesis targeted by SFX-01 and explore whether, like SFN, it exerts its actions via the NRF2 and NF-KB pathways. Osteoclasts generated from the bone marrow (BM) of mice were cultured with SFX-01 at different timepoints to examine each phase of osteoclastogenesis separately. This showed that SFX-01 exerted actions throughout the process of osteoclastogenesis, but had its largest effects in the early osteoclast precursor differentiation stage. Thus, treatment with SFX-01 for the duration of culture, for the initial 3 days differentiation or for as little as the first 24 hours was sufficient for effective inhibition. This aligned with data suggesting that SFX-01 reduced DC-STAMP levels, osteoclast nuclear number and modified cytoskeletal architecture. Pharmacological regulation of NRF2 pathways, via selective inhibitors/activators, supported anti-osteoclastogenic roles for an SFX-01-mediated by NRF2 activation, as well as a need for tight NF-KB pathway regulation in osteoclast formation/function.